Biotie Therapies - Total number of voting rights and capital

New Biotie shares and increase of share capital registered with the trade register

BIOTIE THERAPIES CORP.   STOCK EXCHANGE RELEASE 18 MARCH 2011 at 1.30 pm

Not for release, publication or distribution, directly or indirectly, in whole
or in part, in or into the United States, Australia, Canada, Japan or South
Africa.

New Biotie shares and increase of share capital registered with the trade
register

A total of 35,230,000 new shares offered in Biotie Therapies Corp.'s ("Biotie")
directed share issue announced on 11 March 2011 and the share capital increase
of EUR 26,987,625.36 related to the new shares and the sale of the treasury
shares have been registered with the Finnish Trade Register today on 18  March
2011.

The registered new shares are expected to be traded together with the current
Biotie shares on the stock exchange list of NASDAQ OMX Helsinki Ltd as of 21
March 2011.

The new shares entitle to shareholder rights as of the registration date of 18
March 2011.

After the registration of the new shares with the Finnish Trade Register and the
registration of the share capital increase, the share capital of Biotie is EUR
165,919,181.95 and the total number of shares 387,594,457. Since 14,912,155
Biotie shares are held by Biotie and its subsidiaries, the number of votes
outstanding amounts to 372,682,302.

In Turku, 18 March 2011

Biotie Therapies Corp.
Timo Veromaa, President and CEO

For further information, please contact:
Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail:virve.nurmi@biotie.com
www.biotie.com

DISTRIBUTION:
NASDAQ OMX Helsinki Ltd
Main Media

The information herein may not be distributed or sent into the United States,
Australia, Canada, Japan or South Africa. The information contained herein shall
not constitute an offer to sell or the solicitation of an offer to buy, nor
shall there be any sale of the securities referred to herein in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior to
registration, exemption from registration or qualification under the securities
laws of any such jurisdiction.

The information contained herein does not constitute an offer of securities for
sale in the United States. The securities referenced in this release may not be
offered or sold in the United States absent registration or an exemption from
registration as provided in the United States Securities Act of 1933, as
amended, and the rules and regulations thereunder. Biotie does not intend to
register any portion of the Offering in the United States or to conduct a public
offering of any securities in the United States.

No securities will be offered or sold in any Member State of the European
Economic Area other than to persons who are "qualified investors" within the
meaning of Article 2(1)(e) of the Prospectus Directive.  For the purposes of
this provision, the expression "Prospectus Directive" means Directive
2003/71/EC (and amendments thereto, including the 2010 Amending Directive, to
the extent implemented in the Relevant Member State), and includes any relevant
implementing measure in the Relevant Member State, and the expression "2010
Amending Directive" means Directive 2010/73/EU.

This communication does not constitute an offer of securities to the public in
the United Kingdom. This communication is directed only at (i) persons who are
outside the United Kingdom, (ii) persons who have professional experience in
matters relating to investments falling within Article 19(5) of the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005 (the"FP Order")
and (iii) high net worth entities falling within Article 49(2) of the FP Order,
and other persons to whom it may lawfully be communicated, (all such persons
together being referred to as "relevant persons"). Any investment activity to
which this communication relates will only be available to, and will only be
engaged with, relevant persons. Any person who is not a relevant person should
not act or rely on this document or any of its contents.

Nordea Bank Finland Plc ("Nordea") and Nomura Code Securities Limited ("Nomura")
are acting exclusively for Biotie and no one else in connection with the
Offering. They will not regard any other person (whether or not a recipient of
this release) as their client and will not be responsible to anyone other than
Biotie for providing the protections afforded to their clients, nor for giving
advice in relation to the Offering or any transaction or arrangement referred to
herein. No representation or warranty, express or implied, is made by Nordea or
Nomura as to the accuracy, completeness or verification of the information set
forth in this release.


[HUG#1497998]